Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized trial of intravenous immunoglobulin versus standard therapy for transverse myelitis
2014-002335-34Phase 3Completed
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
- Start
- Oct 2014
- Modality
- Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of IgPro10 in transverse myelitis (TM) and Neuromyelitis Optica Spectrum Disorder (NMOSD) (2 arms), sponsored by Guy's and St Thomas' NHS Foundation Trust. Primary endpoint: Primary responder rate (ASIA improvement at 6 months). Started Oct 2014; status: completed.
02
Drugs
IgPro10
03
Conditions
transverse myelitis (TM)Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on 2014-002335-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002335-34.